Filing Flows › Scynexis (SCYX) › Recalls, complaints & regulation
Scynexis (SCYX): recalls
Scynexis (SCYX) beyond its filings: 0 recalls in the last 12 months (1 in five years, 1 Class I).
Latest recalls
- 2023-10-18 · FDA drug · BREXAFEMME (Ibrexafungerp) tablets 150 mg, 4 count cartons, Rx Only, Manufactured for and distributed by SCYNEXIS, Inc., Jersey City, NJ 07302 NDC 75788-115-04
Scynexis' latest quarter
Scynexis, Q2 2026: revenue $235K (-83% year over year), net earnings $7.4M, operating cash flow −$14.9M. The chart follows the revenue to costs, profit and cash.
Questions
Has Scynexis had any recalls?
1 recall on file over five years from the FDA, CPSC and NHTSA; 0 in the last 12 months.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.